Skip to content
Eylea(aflibercept)
Eylea, Zaltrap (aflibercept) is a protein pharmaceutical. Aflibercept was first approved as Eylea on 2011-11-18. It is used to treat diabetic retinopathy and macular edema in the USA. It has been approved in Europe to treat colorectal neoplasms, diabetes complications, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
eye diseasesD005128
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Eylea, Zaltrap
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Aflibercept
Tradename
Proper name
Company
Number
Date
Products
EyleaafliberceptRegeneron PharmaceuticalsN-125387 RX2011-11-18
2 products
ZaltrapZiv-AfliberceptSanofiN-125418 RX2012-08-03
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
eyleaBiologic Licensing Application2019-08-12
zaltrapBiologic Licensing Application2020-11-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
diabetic retinopathyEFO_0003770D003930—
macular edema—D008269—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX44: Aflibercept
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA05: Aflibercept
HCPCS
Code
Description
J0178
Injection, aflibercept, 1 mg
J9400
Injection, ziv-aflibercept, 1 mg
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228971651729
Lung neoplasmsD008175C34.90—2—114
Drug monitoringD016903———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80—102—112
Hematologic neoplasmsD019337—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50—2———2
Gastrointestinal neoplasmsD005770C26.9—2———2
Salivary gland neoplasmsD012468EFO_0003826D11—2———2
Colorectal neoplasmsD015179—2———2
Ovarian neoplasmsD010051EFO_0003893C56—2———2
GlioblastomaD005909EFO_000051511———1
Urinary bladder neoplasmsD001749C67—1———1
Biliary tract neoplasmsD001661C24.9—1———1
Brain neoplasmsD001932EFO_0003833C71—1———1
Pancreatic neoplasmsD010190EFO_0003860C25—1———1
Show 19 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
Hepatic insufficiencyD0485501————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Disease resistanceD060467————11
MutationD009154————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAFLIBERCEPT
INNaflibercept
Description
Aflibercept, sold under the brandname Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and Europe.
Classification
Protein
Drug classreceptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID862111-32-8
RxCUI1232150
ChEMBL IDCHEMBL1742982
ChEBI ID—
PubChem CID—
DrugBankDB08885
UNII ID15C2VL427D (ChemIDplus, GSRS)
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
7422
Protein name
vascular endothelial growth factor A
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
P15692
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A (Q00731)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zaltrap - Regeneron Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Eylea - Regeneron Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,529 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
23,006 adverse events reported
View more details